On April 10, the National Medical Products Administration (NMPA) convened a special public training program, with online and on-site participation, on inspection, rectification and quality improvement of vaccines and blood products in order to further reinforce oversight of the quality and safety of these medical products.

The training program focused on the overall situation of vaccines and blood products inspections as well as the revisions to the Annex for Sterile Medicinal Products in the Good Manufacturing Practice for Drugs. It emphasized a problem-oriented approach and practical guidance.

It called for efforts to systematically review prominent issues identified during inspections, thoroughly analyze typical case studies and comprehensively guide enterprises in rectifying deficiencies and improving quality. Provincial-level drug regulatory authorities were also urged to further enhance the relevance and effectiveness of their inspections.

More than 800 participants attended the training, including officials from the NMPA’s Department of Drug Regulation, Center for Food and Drug Inspection, Institute of Executive Development and sub-centers for drug evaluation and inspection as well as personnel from 26 provincial-level drug regulatory authorities and heads of manufacturing enterprises.